Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2013

View Archived Issues

Researchers at Apotex present new thymodepressin prodrugs

Biogen Idec and Isis Pharmaceuticals form collaboration for neurological disorders

Cellceutix acquires substantially all PolyMedix assets

NovelMed receives NIH grant to advance development of anti-complement antibody

Experimental pulmonary arterial hypertension inhibited by APT-102

CRAC channel inhibitor RP-3128 demonstrates anti-asthmatic activity

New adenovirus-based vaccines presented by researchers at McMaster University

Noscira discloses novel GSK-3 inhibitors

Swedish Orphan Biovitrum patents new C5 polypeptides

MicroConstants China in-licenses phase II liver cancer drug

Immunovaccine vaccines protect animals against anthrax challenge

Researchers at AbbVie design novel Wee1A kinase inhibitors

BioMotiv and NYU form new company, Orca Pharmaceuticals

Mitsubishi Tanabe Pharma reports the discovery and characterization of novel SGLT2 inhibitors

LTT-Bio Pharma announces changes to pipeline

Nuclea Biotechnologies acquires Wilex

Boehringer Ingelheim completes enrollment in phase IIa interferon-free HCV trial

Lundbeck reveals novel NK-3 receptor antagonists

New MGAT2 inhibitors for the treatment of metabolic syndrome presented

Alcobra reports preclinical data for MG-01CI in mouse model of fragile X syndrome

Omeros submits MAA to EMA for OMS-302

EMA grants orphan drug designation to Patrys antibody for multiple myeloma

First biosimilar monoclonal antibody approved in Europe

Eisai launches anticancer agent Halaven in Russia

Gilead files NDA for idelalisib in treatment of indolent non-Hodgkin's lymphoma

FDA accepts resubmission of NDA for oral treprostinil

FDA advisory committee recommends approval of umeclidinium/vilanterol for treatment of COPD